SparX将在 AACR 2025期间的两场活动中展示 SPX-303（一种双检查点双特异性抗体）的 I期临床更新-动脉网

SparX to Present Phase 1 Clinical Updates of SPX-303, a Dual Checkpoint Bispecific Antibody, at Two Events During AACR 2025

CISION 等信源发布 2025-04-19 03:00



可切换为仅中文







CHICAGO

芝加哥

，

April 18, 2025

2025年4月18日

/PRNewswire/ -- SparX Biopharmaceutical Corp. announced today that it will present clinical updates on its lead asset, SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody, during the Trial-in-Progress poster session at the 2025 American Association for Cancer Research (AACR) Annual Meeting on .

/PRNewswire/ -- SparX生物制药公司今日宣布，将在2025年美国癌症研究协会（AACR）年会的“试验进展中”海报环节展示其主导资产SPX-303的临床更新。SPX-303是一种首创的抗LILRB2/PD-L1双特异性抗体。

April 28

4月28日

, from

，来自

2:00 PM to 5:00 PM

下午2点到下午5点

. The presentation marks the one-year anniversary of the first patient dosing of this novel bispecific antibody in its ongoing Phase 1 clinical trial.

该报告标志着这种新型双特异性抗体在其正在进行的 I 期临床试验中首次患者给药的一周年纪念。

A more comprehensive overview of SPX-303's dual mechanism, which targets both myeloid and T-cell immune checkpoints, will be featured at a Satellite Symposium themed '

SPX-303的双重机制更全面的概述，针对髓系和T细胞免疫检查点，将在一个主题为

Harnessing Super Immunotherapy and ADCs to Redefine the Standard of Care

利用超级免疫疗法和抗体药物偶联物重新定义护理标准

.' Co-hosted by the

“由...共同主办

University of Illinois at Chicago

伊利诺伊大学芝加哥分校

Cancer Center and Yao Yuan—Academy for Pharma Innovation, the symposium will convene expert clinicians, academic investigators, and industry leaders to discuss how next-generation immuno-oncology, known as 'Super IO,' can be synergized with antibody-drug conjugates (ADCs). This innovative approach combines the tumor-targeting precision of ADCs with the immune-activating power of checkpoint inhibitors, aiming to deliver deeper and more durable anti-tumor responses..

癌症中心与姚远——制药创新学院，本次研讨会将召集临床专家、学术研究人员和行业领袖，共同探讨如何将下一代免疫肿瘤学（称为“超级IO”）与抗体药物偶联物（ADC）协同作用。这一创新方法结合了ADC的肿瘤靶向精准性与检查点抑制剂的免疫激活能力，旨在实现更深层次且更持久的抗肿瘤反应。

SPX-303, a first-in-class bispecific antibody targeting LILRB2 and PD-L1, is currently enrolling patients with resistant or refractory solid tumors at a dose level of 20 mg/kg. 'This innovative program represents a significant advancement in macrophage checkpoint blockade and T cell co-engagement strategies,' said Dr.

SPX-303是一种首创的双特异性抗体，靶向LILRB2和PD-L1，目前正在招募耐药或难治性实体瘤患者，剂量为20 mg/kg。博士表示：“这一创新项目代表了巨噬细胞检查点阻断和T细胞共同参与策略的重大进展。”

Gui-.

Gui-。

Dong Zhu

董竹

, CEO of SparX. 'It holds promise as a potential next-generation immuno-oncology therapy—or 'Super IO' booster—for patients with limited treatment options.'

SparX公司的首席执行官表示：“它作为潜在的下一代免疫肿瘤治疗药物或‘超级IO增强剂’，为那些治疗选择有限的患者带来了希望。”

The SPX-303 poster will be presented at Poster #CT116-11 in the Phase I Clinical Trials in Progress session at McCormick Place,

SPX-303海报将在麦考密克展览中心的I期临床试验进展会议的#CT116-11海报展位展示。

Chicago

芝加哥

, on

，打开

April 28

4月28日

, from

，来自

2:00 to 5:00 PM

下午2:00到5:00

. The Satellite Symposium will be held at the Trump International Hotel & Tower

卫星研讨会将在特朗普国际酒店大厦举行。

Chicago

芝加哥

(401 N Wabash Ave,

（北瓦巴什大街401号，

Chicago, IL

伊利诺伊州芝加哥市

60611). SparX welcomes attendees to visit its exhibition booth during the symposium and strongly encourages early registration via the [

60611). SparX欢迎与会者在研讨会期间参观其展览展位，并强烈鼓励通过[进行早期注册。

registration portal

注册门户

] to secure a seat.

] 以确保获得一个席位。

About SPX-303

关于SPX-303

SPX-303 is a first-in-its-class bispecific antibody therapy designed to simultaneously inhibit LILRB2 and PD-L1, two critical immune checkpoint proteins often hijacked by cancer cells. The program represents a novel immunotherapy approach aimed at activating both myeloid and lymphoid immune responses..

SPX-303是一种首创的双特异性抗体疗法，旨在同时抑制LILRB2和PD-L1，这两个常被癌细胞劫持的关键免疫检查点蛋白。该计划代表了一种新颖的免疫治疗方法，旨在激活髓系和淋巴系免疫反应。

About SparX Biopharmaceutical Corp.

关于斯帕克斯生物制药公司

SparX Biopharmaceutical Corp. is a research-driven, development-stage biopharmaceutical company dedicated to advancing transformative nanobody-based therapeutics through innovation, global collaboration, and scientific leadership—bringing next-generation treatments to patients worldwide. Leveraging advanced platforms such as SAILING.

SparX生物制药公司是一家以研究为导向、处于开发阶段的生物制药公司，致力于通过创新、全球合作和科学领导力推动变革性的基于纳米抗体的治疗药物的发展，为全球患者带来下一代治疗方案。公司依托SAILING等先进平台。

™

and its proprietary Nab2 bi-ADC technology, SparX integrates AI-enabled discovery with robust in-house cGMP manufacturing capabilities to drive innovation from target identification through clinical development. With integrated antibody discovery systems and state-of-the-art facilities in

通过其专有的Nab2双ADC技术，SparX将人工智能驱动的发现与强大的内部cGMP生产能力相结合，推动从靶点识别到临床开发的创新。凭借集成的抗体发现系统和最先进的设施，

Chicago

芝加哥

, SparX is well-positioned to support clinical and commercial-scale production, enabling its evolution into a fully integrated, independent biopharmaceutical company.

，SparX 有能力支持临床和商业规模的生产，有助于其发展成为一家完全整合、独立的生物制药公司。

For more information about the SPX-303 study, please visit:

有关SPX-303研究的更多信息，请访问：

www.clinicaltrials.gov

临床试验官网

(Identifier: NCT06259552)

（标识符：NCT06259552）

SOURCE SparX Biopharmaceutical

来源：SparX生物制药

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?